The Government Wants to Turn Your Body Into a Dashboard

Phase 2 runs 18 months and moves into early testing inside living systems (in vivo experiments, for the science nerds). This is where chiplets have to survive contact with actual biology, not just a lab.

Phase 3 is the one-year sprint to the finish: human factors testing and clinical trials. Can real people wear these things comfortably? Do the readings hold up when someone's sweating through a workout or sleeping on their side?

There's a clever twist baked into the structure. At each phase transition, teams must add new biomarkers to their sensor lineup. ARPA-H calls these "remixes." It's like a cooking competition where the judges keep throwing in surprise ingredients; you can't just perfect one dish and coast.

The Bigger Bet Behind the Biosensors

Delphi doesn't exist in a vacuum. ARPA-H is building an entire portfolio of biosensor programs, and the combined investment tells a story about where federal health R&D is heading.

Take OCULAB, a parallel program that funds four research teams (including a group at MIT) to develop sensors that literally sit inside your tear duct. These tiny devices analyze tear chemistry to monitor conditions like dry eye disease, diabetes, and depression.

Delphi's exact funding hasn't been disclosed yet; it will depend on the quality of proposals that come in. That's serious money for sensor technology that could eventually cost pennies per chiplet to produce.

The agency also runs REACT, a program led by the same Paul Sheehan, which develops implantable bioelectronic systems for automated monitoring and drug delivery in chronic conditions. If REACT is the "living pharmacy" inside your body, Delphi is the "living dashboard" on your skin.

Why This Matters More Than Another Fitbit Competitor

Let's zoom out. The wearable health market is already crowded with consumer gadgets tracking steps, sleep, and heart rate. So why should a government biosensor program matter to the biotech world?

Because there's a massive gap between consumer wellness trackers and clinical-grade diagnostics. Your Apple Watch can flag an irregular heartbeat, which is genuinely useful. But it can't tell your doctor whether your inflammation markers are creeping up, whether your antidepressant is at the right level in your blood, or whether your immune system is gearing up for a flare.

That's the gap Delphi targets. The program aims to create sensors that bridge consumer convenience with clinical depth. Imagine a patch on your arm that feeds real-time biomarker data to your care team, adjusting treatment before you even feel worse. It's the difference between checking the weather once a day and having a live radar on your phone.

This also aligns with a broader push at HHS. Secretary Robert F. Kennedy Jr. has publicly advocated for widespread wearable use by decade's end, envisioning a future where tracking glucose and pulse is as routine as checking your phone. The FDA has even piloted programs that could waive certain premarket requirements for devices collecting real-world data.

The Challenges Nobody's Talking About

Before we get too starry-eyed, some reality checks.

Miniaturization is brutally hard. Shrinking a lab-grade sensor into something comfortable enough to wear all day, while maintaining accuracy, remains one of the biggest unsolved problems in biomedical engineering. Flexible materials, power management, and wireless data transmission all have to work simultaneously in a package smaller than a Band-Aid.

Real-world accuracy is a different beast than lab accuracy. A sensor that performs beautifully in controlled conditions might struggle when someone's running a fever, sweating profusely, or just living their normal, messy human life. Phase 3's human factors testing will be the moment of truth.

And then there's the question of data security. Continuous biological monitoring generates incredibly intimate information. Sheehan emphasized that the data would be "secure," but the details of how that security works will matter enormously as these devices move toward real patients.

The Bottom Line

ARPA-H is betting that the future of health monitoring isn't a bigger, fancier smartwatch. It's a constellation of tiny, modular chiplets that read your body's deepest signals and snap together like building blocks. The Delphi program gives researchers 4.5 years and potentially north of $100 million to prove it.

If it works, we're looking at a fundamental shift: from reactive medicine (you feel sick, you go to the doctor) to proactive, continuous care that catches problems before they become crises. If it doesn't, well, at least your Fitbit still counts steps.

Proposals are due April 8. The race to build biology's dashboard is officially on.

Two Pharma Giants Just Crashed the Obesity Party on the Same Day

AbbVie and Regeneron dropped obesity drug data on the same day, and neither is trying to be the next Ozempic. One showed nearly 10% weight loss in just 12 weeks through a completely different mechanism; the other posted 19% weight loss with dramatically fewer side effects than Zepbound.